FDA 510(k) Redaction Proposal For All 510(k)s Lacks Justification - Industry
This article was originally published in The Gray Sheet
FDA's proposal that all 510(k) sponsors must provide redacted versions of their submission upon clearance is unnecessary given the small number of Freedom of Information Act requests, the National Electrical Manufacturers Association asserts in March 20 comments to the agency.
You may also be interested in...
Copyrighted material that has not been redacted by 510(k) applicants would be released on the Internet under FDA's proposed rule for redaction of cleared 510(k)s. Comments are due by March 20.
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.